Biotech VC Funds

StartX, established in 2011 by Stanford alum Cameron Teitelman, is a non-profit startup accelerator and founder community affiliated with Stanford University. It operates with a unique zero-equity model, providing extensive support and resources to entrepreneurs without taking any ownership in their companies. This model fosters an open and collaborative environment where founders can freely share challenges and seek mentorship. StartX focuses on a diverse range of sectors, welcoming companies at various stages of development. Their community includes over 1,600 founders and 75 tenured Stanford professors, with notable alumni such as Lime, Lucira Health, and Branch Metrics. Companies in the StartX program are significantly more likely to reach valuations of $100 million or more, with 18 companies achieving unicorn status. The accelerator is also home to StartX Med, which specifically supports medical and biotech startups, leveraging partnerships with Stanford Health Care and access to specialized lab facilities. StartX Med has launched over 200 companies, with a remarkable 91% demonstrating commercial viability. Located in Stanford Research Park, StartX benefits from proximity to Silicon Valley's vibrant ecosystem, including investors on Sand Hill Road and leading legal firms, providing ample networking and growth opportunities for its startups​.

Steel Wolf Ventures (SWV) is a boutique, impact-oriented venture firm founded in 2011 and based in Beverly Hills, California, led by Founder and Managing Partner R. Victoria Jodis, a California entrepreneur and media producer. Co-founder and partner John Schum is a veteran attorney with deep cannabis-industry experience; the team also includes Principal Mark Dirkse, corporate attorney Robert Moore and board member Les Goodman. SWV runs a self-described hybrid funding model that rejects the traditional investment-bank structure: it charges modest upfront fees for expenses, team evaluation and strategic development, takes equity, and embeds with client-founders as long-term advisors, board members and partners. It targets post-seed and 'evolved' pre-IPO startups in potential billion-dollar markets that are beyond friends-and-family money but not yet ready for institutional rounds. Focus sectors span biotech and precision medicine, medtech and health, technology and AI, agtech, SaaS, lifestyle, CBD and cannabis, clean energy, and real estate development. The firm positions itself as a lead investor on rounds around $500K and on raises exceeding $1M. Named portfolio companies include Lumoptik, a surgical-devices business; Apothēka, a healthcare enterprise-systems company; and Pecan TV, in movies, music and entertainment. SWV also manages a venture fund called Silver Wolf. With a small, advisory-driven team and a hands-on model that blends equity investment with operational partnership, Steel Wolf Ventures backs founders bridging the gap between early funding and institutional capital.

SteelSky Ventures is a female-led venture capital fund that specializes in women's healthcare. Founded by Maria Toler Velissaris, the fund aims to fill a critical gap in the VC market by investing in companies that improve access to care, medical outcomes, and health infrastructure for women. With $72 million in assets under management, SteelSky is the largest VC fund focused exclusively on women’s health. The fund invests across various sectors, including medical devices, digital health, consumer health, and ePharmacy​. SteelSky primarily targets late-seed and Series A rounds, focusing on startups with proven product-market fit, typically generating $1-2 million in revenue. The portfolio is rich in innovation, supporting companies like Zipline, which uses drones to deliver life-saving medical supplies to remote areas, and Raydiant Oximetry, a company developing more accurate fetal distress monitoring​. The fund's approach is to back scalable, impact-driven ventures that address pressing challenges in women's healthcare, particularly those impacting underrepresented communities​. With a strong presence across the U.S., SteelSky benefits from strategic partnerships with major healthcare organizations like Blue Shield of California and the American Hospital Association, as well as financial institutions like Bank of America and JPMorgan​. Entrepreneurs looking to engage with SteelSky should emphasize their product's real-world impact on women’s health, scalability, and innovative approach to addressing healthcare disparities.

SternAegis Ventures is the private equity and venture capital division of Aegis Capital Corp., founded in 2012 and based in New York City. It is led by CEO Adam K. Stern, who has headed Private Equity Banking at Aegis Capital Corp. since 2012, and partners with entrepreneurs and early-stage companies to build brands with long-term investment value, adding value through capital formation and strategic relationships. The firm runs a team of roughly 20 people, including about 10 partners. SternAegis invests primarily at Series A in US-based startups across a broad set of sectors, prominently technology including software, web marketplaces and SaaS, IT and media, alongside biotechnology, medical devices, hospital services, life sciences, healthcare and energy. As a lead investor, it brings investment banking, merchant banking, transaction execution and strategic consulting to accelerate portfolio company growth. As of 2022 it had invested in around 20 companies, with a track record that includes 11 IPOs and one acquisition. Notable portfolio names include Zoomcar, DarioHealth and Orchestra BioMed, and a recent highlight was leading the $11.8M Series A round of Amplifica. Brokerage and advisory products are offered through Aegis Capital Corp., a member of FINRA and SIPC. By combining venture investment with a full-service investment-banking platform, SternAegis Ventures supports early-stage founders from initial capital formation through to public-market and strategic exits.

Storm Ventures is a venture capital firm specializing in early-stage investments in B2B software startups. With over 23 years of experience, Storm Ventures has a distinguished portfolio that includes companies such as Marketo, MobileIron, and Talkdesk. The firm focuses on sectors like SaaS, enterprise infrastructure, cybersecurity, and artificial intelligence, helping startups navigate from inception to becoming industry leaders. Based in Silicon Valley, Storm Ventures boasts a global investment team with additional presence in South Korea and Germany. The firm's strategy is centered on supporting startups through critical growth phases, providing resources to unlock growth and achieve product-market fit. They prefer startups with happy customers, innovative software, and a strong team. Storm Ventures often leads funding rounds, bringing in-depth expertise and a hands-on approach to their investments. Key team members include Managing Directors Ryan Floyd, Alex Mendez, and Tae Hea Nahm, who bring extensive experience in scaling B2B companies. The firm’s methodology involves working closely with founders, providing not only capital but also strategic guidance and operational support to drive growth and success.

Story Ventures, based in New York City and founded in 2016, focuses on early-stage investments in frontier technology. Their portfolio spans several sectors, including sensory systems, data processing, and machine intelligence. Notable investments include Particle Health, Motorq, and Prism Data, demonstrating their commitment to innovative data automation solutions. The firm emphasizes capturing and leveraging proprietary data to drive impactful decision-making and solve complex problems. Story Ventures supports companies from the very first check, helping them scale and secure further funding from top-tier venture capital firms. Their investment strategy prioritizes founders tackling audacious challenges to create lasting impact. Key team members include Brian Yormak, who specializes in mobility investing, and Teddy McGehee, who manages legal and financial processes. They are joined by Reilly Simmons, focusing on generative AI applications, and Melissa Cook, who oversees operations. Story Ventures launched a Scout Program in 2022 to work with entrepreneurial individuals at the forefront of technology development, offering them investment opportunities and a community of angel investors. This approach has helped build a diverse and dynamic portfolio aimed at shaping the future of data automation and machine intelligence.

Stout Street Capital, based in Denver, Colorado, is a venture capital firm that focuses on investing in early-stage tech startups. Founded in 2017 by Clay Gordon and John Francis, the firm targets pre-seed and seed-stage companies that are seeking to raise $1 million or more. They typically invest in rounds that provide 12-24 months of runway and prefer startups with post-product and post-revenue, usually generating $20-30k or more in monthly revenue. The firm has a diverse portfolio with over 66 companies and has made 86 investments to date. Notable investments include companies like Optera, which focuses on clean technology and sustainability, Schola, an education technology firm, and KredosAI, a fintech software company. Stout Street Capital also played a significant role in investments for 401GO, Curate, and OpenTug. Stout Street Capital emphasizes supporting founders by providing extensive resources and fostering a network to help scale their businesses. They invest primarily in the US and Canada, excluding major tech hubs like San Francisco, New York, and Boston. The firm is known for its commitment to transparency and its efficient due diligence process, typically completed within 2-3 weeks. Their most common check size is around $250K.

Stray Dog Capital is a forward-thinking venture capital fund dedicated to investing in early-stage companies within the food and biotech sectors, particularly those advancing plant-based, cultivated, and precision fermentation technologies. Notable investments include Beyond Meat, Miyoko’s Creamery, and BlueNalu, companies renowned for their innovative approaches to sustainable food production. The fund, headquartered in Leawood, Kansas, typically invests between $500K and $5M per round, often leading these investments and providing robust strategic support to portfolio companies. Stray Dog Capital focuses on the U.S. market but has a global perspective, with investments in companies like Sunfed in New Zealand and Aleph Farms in Israel. The fund's investment strategy emphasizes transformative technologies that promise significant environmental and social impacts, aligning with their mission to create a more humane and sustainable food system. Their portfolio companies reportedly produce 98% fewer farm emissions compared to traditional meat industry standards. The leadership team, including CEO Lisa Feria and partners like Johnny Ream, leverages deep industry expertise and a hands-on approach to nurture startups. Stray Dog Capital values direct pitches from passionate entrepreneurs who can demonstrate innovative solutions and scalable business models. For startups aiming to catch their attention, showcasing technological uniqueness and alignment with sustainability goals is crucial. Overall, Stray Dog Capital is committed to pioneering a healthier future through strategic investments and active collaboration with visionary founders in the alternative protein space.

Stride.VC is a London-based venture capital fund focused on early-stage investments, particularly at the pre-seed and seed stages. Co-founded in 2018 by Fred Destin and Harry Stebbings, the firm aims to back startups that are disrupting traditional industries with technology. Stride has a particular interest in sectors like AI, SaaS, fintech, e-commerce, and HR tech. Notable investments include well-known names like Deliveroo, Cazoo, Dailymotion, and Hopin. Stride typically invests between £250,000 to £4 million and is known for its hands-on approach with founders. Their philosophy emphasizes conviction and clarity, preferring prototypes over PowerPoints and staying actively engaged where it counts, while also stepping back when it's time for the entrepreneurs to lead. Their London base positions them as a key player in Europe, although their portfolio also extends to other global tech hubs. Stride is selective with its investments, often leading rounds but with high standards for both the companies and their founders. Their approach to board meetings is famously collaborative, encouraging dialogue through whiteboard sessions to stimulate creative problem-solving. The team includes notable partners like Gabbi Cahane and Cleo Sham, who bring deep expertise from across tech and venture. Stride's recent activity has seen them back innovative startups like TechWolf and Triver, reflecting their ongoing commitment to bold, forward-thinking ventures.

STV (Saudi Technology Ventures) is the largest venture capital fund in the Middle East, managing an $800 million fund focused on the MENA region’s technology ecosystem. The firm has a strong track record of identifying and backing high-growth tech startups, aiming to drive innovation in industries like e-commerce, fintech, logistics, and communications. Notable investments include companies like Careem, which was acquired by Uber, and Unifonic, a cloud communication platform. STV primarily targets early to growth-stage investments, with a clear emphasis on startups that have the potential to become regional leaders or even unicorns. The firm’s strategy aligns with Saudi Arabia's Vision 2030, which promotes tech-driven economic diversification. STV actively supports its portfolio companies through capital, strategic advice, and leveraging its vast network across the region, including government and private sector connections. Geographically, STV focuses on the MENA region but with a particular emphasis on Saudi Arabia, a booming market for venture-backed startups. Saudi Arabia’s strong GDP and expanding digital infrastructure make it the hub for tech startups in the region. Led by CEO Abdulrahman Tarabzouni, STV's team includes a mix of seasoned entrepreneurs and investment professionals who play a hands-on role in nurturing their portfolio companies. STV looks for startups with strong market traction and a clear path to scale, aiming to create regional tech giants capable of IPO or large-scale exits.

Sukna Ventures is an early-stage venture capital firm based in Riyadh, with a strong focus on digital transformation across the MENA region. The firm backs startups from pre-seed to Series B, particularly in sectors like fintech, gaming, education, health tech, and enterprise software. Their geographic focus spans key markets, including Saudi Arabia, UAE, Jordan, Egypt, and Bahrain, aligning with regional growth trends in technology and innovation. Sukna Ventures is dedicated to investing in entrepreneurs who are building the next wave of high-growth ventures, leveraging cutting-edge technologies such as AI, machine learning, blockchain, and AR/VR. The firm supports companies that adapt to evolving market dynamics and regulations, empowering founders to scale their businesses in a rapidly transforming digital economy. With offices in Riyadh, Jeddah, and Abu Dhabi, Sukna Ventures is well-positioned to tap into local and regional opportunities, while maintaining a global perspective. The team, comprised of seasoned investors and entrepreneurs, plays a hands-on role in nurturing portfolio companies, offering strategic advice and access to a broad network. Notable investments include startups like Quantums, an ad-tech solution enhancing e-commerce media, and Earn Alliance, a platform empowering gamers in the web3 space. Sukna Ventures prides itself on creating meaningful impact, helping ventures reshape how we live, work, and play in the digital age.

Sultan Ventures is a boutique early-stage venture capital firm founded in 2009 and based in Honolulu, Hawaii. It was co-founded by managing partners Omar Sultan and Tarik Sultan, with Dr. Aya Sultan as a founding partner; Meli James serves as Head of New Ventures, directed the XLR8UH accelerator, and is President of the Hawaii Venture Capital Association. The firm is largely sector-agnostic but concentrates on pre-seed and seed financing rounds alongside preferred investment partners, typically as a co-investor. Its sector interests span healthcare, biotech, edtech, fintech, entertainment, information technology, aviation, energy, food and beverage, and consumer products. Sultan Ventures looks for visionary founders building sustainable businesses, placing heavy emphasis on education and strong team dynamics, and provides due diligence, deal sourcing, capital-raise and business-planning support through its network of experts and investors. It operates XLR8UH, an award-winning venture accelerator investing in University of Hawaii entrepreneurs and technologies that Forbes named among the top 30 US accelerators, and manages the Upside Fund, which can invest up to $600K in companies using University of Hawaii intellectual property. As of 2016 it had invested in around 23 companies, with notable holdings including RedVox Infrasound, MeetingSift and SimpliFed. The firm has expanded internationally through the acquisition of Acasia Group, targeting opportunities in the Middle East and Africa. By anchoring itself in Hawaii's university and startup ecosystem, Sultan Ventures backs founders and commercializes academic innovation.

Summit Partners is a global investment firm that focuses on growth equity, managing more than $37 billion in capital. Founded in 1984, it has invested in over 550 companies across key sectors such as technology, healthcare, and growth products & services. Summit is known for backing companies with strong growth potential, offering both minority and majority investments, with a typical check size ranging from $10 million to over $500 million. The firm partners with companies that demonstrate leadership in their respective industries, providing not just capital but also strategic resources through its Peak Performance Group. This dedicated team supports portfolio companies in areas like operations, M&A, and capital markets, ensuring they scale efficiently. Summit has a strong global presence, with offices in Boston, Menlo Park, New York, London, and Luxembourg, and focuses heavily on profitable growth as a key driver of long-term value creation. Notable portfolio companies include technology giants like Klaviyo and cybersecurity firm Darktrace. Summit's hands-on, collaborative approach has made it a top choice for companies looking to scale rapidly while maintaining profitability​.

Sunsino Venture Group is one of Taiwan's leading multi-asset alternative investment firms, founded in 1993 and headquartered in Taipei. Over a track record spanning more than three decades it has cumulatively managed 16 venture investment funds, including vehicles backed by Taiwan's government and National Development Council, and currently oversees roughly NT$4 billion, about US$150 million, in assets. The firm is led by Chairman and Managing Partner Vincent Wang, a Wharton MBA, chairman of the Taiwan Angel Investors Association and board member of the Taiwan Venture Capital Association, alongside Partner and STARTUP101 CEO Cami Lu. Sunsino invests in innovative and disruptive startups in healthcare, technology and software, with particular emphasis on AI, IoT, medtech and ESG companies that have working demos or MVPs validated by reputable industry players or initial sales. It also backs enterprise applications, food and agriculture tech and life sciences, supporting global entrepreneurs across its core markets of Taiwan, Japan, Korea, Southeast Asia and the United States. The firm writes cheques typically in the US$5 to 10 million range, investing from Series A through later growth rounds as a lead investor while advising founders on operating strategy, follow-on fundraising and exit planning. It has invested in over 200 companies with roughly 80 IPO and M&A outcomes; notable names include Cardival Medical, Loopd and Advanced Analogic Technologies. With three decades of fund management and a pan-Asian and US footprint, Sunsino Venture Group is an established growth-stage technology and healthcare investor.

Sunstone Life Science Ventures is an independent European venture capital firm founded in 2007 and headquartered in the Copenhagen area of Frederiksberg, Denmark. Originally the life-science arm of Sunstone Capital, it invests exclusively in early-stage life science companies developing novel therapeutics for humans, with a particular focus on specialty pharmaceuticals and orphan drugs; notably, it does not invest in medical technologies or diagnostics. The firm manages approximately EUR 500 million across multiple funds and acts as a lead investor. Sunstone typically makes its initial investment when companies are raising Series A or Series B rounds, backing programs supported by solid in-vivo preclinical data and a well-understood mechanism of action. Its early funds drew capital from leading Nordic institutions including Industriens Pension, Nordea Life & Pensions, Tryg i Danmark, MP Pension, Lønmodtagernes Dyrtidsfond and the Danish government fund Vaekstfonden. The investment team is led by Managing General Partner Søren Lemonius, Chairman and General Partner Peter Benson, and General Partners Dr Sten Verland and Dr Claus Andersson. Since inception Sunstone has backed more than 50 therapeutics companies and helped originate around 20 approved products, with over 20 successful IPOs and M&A exits. Notable portfolio companies include Zealand Pharma, Zymenex, IO Biotech, Minervax, Galecto Biotech, Alligator Biosciences, Orphazyme, Nuevolution and Symphogen; its most recent exit was JenaValve in July 2024. With deep Nordic institutional backing and a specialized therapeutics focus, Sunstone is a leading European life-science investor.

Supply Change Capital is a venture capital firm based in Los Angeles that focuses on transforming the food system by investing in early-stage companies at the intersection of food, culture, and climate. Founded in 2020 by Noramay Cadena and Shayna Harris, the firm aims to back startups developing innovative solutions for a more sustainable and inclusive food ecosystem. With a $40 million fund, Supply Change Capital has already made significant strides by investing in companies like Aqua Cultured Foods, Partake Foods, and Hyfé. The firm emphasizes the importance of cultural inclusivity and environmental sustainability, seeking to address global food system challenges such as inefficient supply chains, high greenhouse gas emissions, and limited access to healthy, culturally relevant food options. Supply Change Capital primarily invests in diverse founders and food tech innovations that improve sustainability and equity across the food value chain, from farm to fork. Their approach combines financial support with deep operational expertise, leveraging the founders' backgrounds in both the food and tech sectors to provide strategic guidance and access to a strong network. This mission-driven approach not only fosters innovation but also aims to create systemic change in the food industry for the betterment of both people and the planet.

Susa Ventures is a seed-stage venture capital firm based in San Francisco, named after the Susa family of mountain gorillas in Rwanda. The firm focuses on investments in sectors such as fintech, healthcare, logistics, enterprise software, and infrastructure and development tools. Susa Ventures seeks out businesses with strong compounding moats, like proprietary data, economies of scale, and network effects. Founded by Seth Berman and Chad Byers, Susa Ventures has backed notable companies like Robinhood, Flexport, and Viz.ai. The firm typically invests between $1 million and $3 million in seed rounds and is known for being a supportive and accessible partner to its portfolio companies. Susa Ventures prides itself on creating a deeply connected community of founders, investors, operators, advisors, and service providers. The team at Susa Ventures includes experienced professionals from various backgrounds, all committed to helping entrepreneurs succeed. Their investment process involves a few introductory meetings followed by a full partner meeting and thorough reference checks.

Sustainable Ventures is the UK’s foremost climate tech investor and ecosystem builder, dedicated to advancing sustainable innovation since 2011. With a focus on early-stage climate tech startups, the firm has invested in over 45 companies across six funds, making it the most active investor in this space. Sustainable Ventures supports businesses through a comprehensive ecosystem approach that combines investment, grant writing, co-working spaces, and hands-on advisory services. Their pre-seed investments are targeted at high-potential climate tech ventures qualifying for SEIS and EIS schemes, with follow-on funding regularly secured to help scale these companies. With hubs in London, Cambridge, and Manchester, Sustainable Ventures has created a thriving climate tech community of over 700 startups, generating more than 6,000 green jobs and raising £1.1 billion in equity funding to date. Their portfolio showcases a variety of innovative startups, such as Sunswap, which is working to decarbonize transport refrigeration, and Biophilica, which develops plant-based alternatives to leather. Additionally, Sustainable Ventures has facilitated game-changing startups like Rovco, a leader in unmanned subsea vehicles for renewable energy, and Airex, which offers smart air bricks for energy efficiency in homes​. Their strategy emphasizes solving real customer problems, future-proofing the economy while addressing urgent climate challenges. In partnership with corporate giants like Barclays and supported by a strong investor network, Sustainable Ventures is rapidly expanding across the UK to empower climate tech entrepreneurs and help accelerate the transition to a net-zero future​.

SV Angel, founded by Ron Conway in 2009, is a prominent venture capital firm based in San Francisco. Renowned for its focus on early-stage investments, particularly in technology and software sectors, SV Angel has been instrumental in the growth of numerous high-profile startups. Some of its notable investments include Stripe, Reddit, Notion, Headspace, Color, Patreon, Credit Karma, Poshmark, and GitHub. The firm is highly active in the startup ecosystem, making over 1,100 investments and achieving more than 450 exits. Significant exits include companies like Airbnb, Coinbase, DoorDash, and Slack. SV Angel is known for its founder-focused approach, providing not only capital but also strategic support without taking board seats, thus allowing founders greater operational freedom. SV Angel typically invests in seed rounds with average check sizes around $150,000. They do not lead funding rounds but prefer to collaborate with other investors. The firm has a history of supporting startups through special purpose vehicles for late-stage investments and growth equity funds, like the $269 million fund raised in 2022. The firm's leadership includes Ron Conway and his son Topher Conway, who continue to emphasize a community-oriented, hyper-engaged investment style. This strategy has positioned SV Angel as a vital player in fostering innovation within the tech industry.

SV Health Investors is a leading healthcare-focused venture capital firm with over 30 years of experience, specializing in biotechnology, medical devices, and healthcare services. Notable investments include companies like American Well, Nimbus Therapeutics, and Bicycle Therapeutics. Their portfolio spans groundbreaking areas such as precision medicine, dementia therapeutics, and digital health. The firm’s industry focus is deeply rooted in life sciences, with a particular emphasis on biotechnology, medtech, and healthcare growth opportunities. Their investments target startups across all stages, from early innovation to growth phases, with a sharp focus on transforming healthcare through innovative treatments. SV Health Investors operates globally, with key offices in Boston and London, primarily focusing on the US and UK markets. Their strategy revolves around creating value through a hands-on approach, often leading rounds and collaborating closely with entrepreneurs. They are known for their in-depth sector knowledge, especially in complex therapeutic areas, and provide capital along with operational expertise to help companies scale. The average check size varies by stage and sector, and SV is actively involved in both early-stage biotech ventures and more mature growth companies. The team is led by seasoned experts like Kate Bingham and Nikola Trbovic, combining extensive industry experience with a commitment to fostering diversity in their investments. Entrepreneurs seeking to approach SV should highlight strong scientific innovation and a clear path to clinical impact, as the fund prioritizes cutting-edge breakthroughs with high potential.

SV Latam Capital is a San Francisco-based venture capital firm that focuses on early-stage investments across Latin America. Founded in 2013 by Consuelo Valverde, the firm is dedicated to empowering innovative startups that address critical global challenges, particularly in the realms of health, sustainability, and technology. The firm’s mission is to support bold founders who are building businesses that have a positive impact on people and the planet. SV Latam Capital’s investment strategy emphasizes identifying and backing tech and science-driven companies with the potential to create transformative solutions. The firm’s portfolio includes companies that are pioneering advancements in sectors such as healthcare, clean energy, and fintech, reflecting its commitment to making a meaningful impact through its investments. The firm operates with a unique approach, leveraging its Silicon Valley roots to provide capital, mentorship, and strategic support to Latin American entrepreneurs. This approach has attracted a diverse group of investors, including notable names like Chris Sacca and PayPal, who recognize the significant potential in the Latin American market. SV Latam Capital has raised multiple funds, including its $22 million Fund II, which closed in 2021. This fund is designed to support the next generation of Latin American entrepreneurs, with a focus on scaling innovative solutions that can address global challenges. With its strong network and deep expertise, SV Latam Capital is well-positioned to continue driving positive change and fostering the growth of high-impact startups across the region​.

Silicon Valley Bank (SVB) has carved out a unique niche in the venture capital world by focusing on the innovation economy. Notable investments include high-profile startups like Airbnb and Uber, reflecting SVB’s emphasis on early-stage, high-growth companies. SVB’s industry focus spans technology, life sciences, healthcare, and premium wine sectors, providing tailored financial services to meet the specific needs of these industries. Geographically, SVB is active globally, with a significant presence in the United States, Europe, and Asia. This extensive reach allows them to support startups with ambitions to scale internationally. SVB’s investment strategy involves participating in early-stage funding rounds and providing venture debt, which helps companies extend their runways without diluting equity excessively. They typically lead funding rounds and often take board seats to offer strategic guidance. SVB has been active lately, with consistent investment activity even during market slowdowns. They prefer a hands-on approach, often advising companies on financial planning and operational efficiency. The average check size varies, but they are known for their substantial investments that can significantly propel a startup’s growth. Key team members include industry veterans like Greg Becker, who brings decades of experience in banking and venture capital, based in the firm's headquarters in Santa Clara, California. For startups looking to engage with SVB, a warm introduction through a shared connection or a strong business plan highlighting scalability and innovation can be effective ways to get noticed. SVB values relationships built on trust and strategic alignment, making it crucial for startups to demonstrate how they fit into SVB’s vision of the future.

THRIVE AgriFood, operated by SVG Ventures, is a premier global investment and innovation platform focusing on agtech and foodtech startups. Since its inception in 2010, THRIVE has built a robust portfolio of over 80 investments, including notable companies like Tortuga Agtech, Farmwise, and MilkMoovement. The firm is recognized as the most active AgTech investor globally, providing not just capital but also comprehensive support through its accelerator programs and strategic partnerships with leading corporations like Land O’Lakes, Bayer, and Shell. Based in Silicon Valley, THRIVE collaborates with a vast network of over 10,000 startups from 100 countries. Their investment strategy spans from Seed to Series A rounds, focusing on sustainable and innovative technologies that address critical challenges in the food and agriculture sectors. The firm also runs various programs and challenges to identify and support high-potential startups globally​. For startups, THRIVE offers extensive resources, including mentorship, market access, and corporate partnerships, designed to accelerate growth and drive impactful innovation. Their comprehensive approach ensures that startups are well-equipped to scale and succeed in the competitive agtech and foodtech landscapes.

Switch Ventures, founded by Paul Arnold in 2014, is a venture capital firm based in San Francisco, California. The firm focuses on early-stage investments, aiming to back talented founders who diverge from conventional paths to create impactful startups. Switch Ventures has a strong commitment to diversity, with 70% of its portfolio companies founded by women or people of color. The firm has made 67 investments and achieved 10 notable exits, including companies like The Athletic, Mode Analytics, and Policygenius. Switch Ventures' diverse portfolio includes startups across various sectors such as fintech, health tech, and enterprise software. Notable investments include Pluto, Gridwise, and Turtle Health. Switch Ventures emphasizes building a strong community of founders and providing them with the support necessary to secure follow-on funding and achieve substantial growth. The firm is known for its founder-friendly approach and deep involvement in the startups it backs​.

Synergy Ventures is a Menlo Park, California-based venture capital firm active in medical technology and venture capital since 1996, specializing in seed and early-stage investment in the medical device, medical technology, healthcare and biotechnology sectors. The firm seeks US medical device startups that can demonstrate clinical efficacy early and that have strong potential for strategic partnership and acquisition, typically writing initial checks of $250K to $1M alongside hands-on strategic guidance, usually as a co-investor. A distinctive feature is its affiliated consulting company, Synergy Partners International, which develops investment, distribution and strategic partnering relationships between US medical technology companies and Japanese corporate and financial clients, giving portfolio companies access to Japan and Pacific Rim partnerships and acquisition opportunities. Across its Synergy Ventures funds and Synergy Partners International, the firm reports participating in over $1 billion in equity and other financial transactions involving more than 70 private US medical technology companies. Its portfolio has produced multiple IPOs and acquisitions, including Align Technology, Omnicell and Companion Medical, with notable holdings such as Pulse Biosciences, Ocugen, Endra Life Sciences, Imprimis Pharma, Aqua Metals, ClearSign and Ideal Power. The firm is led by co-founders and managing directors Allan Johnston, Ph.D., formerly head of late-stage medtech private equity at Berkeley International Capital Corporation and a program manager at SRI International, and Robert Okun, M.I.M., a veteran of Japan and Pacific Rim syndication, fundraising and strategic equity arrangements. Synergy Ventures pairs medtech investing with a unique US-Japan partnering platform.

Syngenta Group Ventures is a venture capital arm based in Basel, Switzerland, focusing on innovative agri-food technologies and business models. They aim to transform agriculture by supporting startups that address global challenges such as climate change, food security, and sustainable farming. Notable investments include Sound Agriculture, which develops climate-smart agricultural solutions; Greeneye Technology, an AI-driven precision spraying system; and BioPhero, which creates sustainable biological alternatives to chemical pesticides. The fund primarily invests in early to late-stage companies across diverse geographies, with significant activity in North America, Europe, and Asia. Syngenta Group Ventures typically takes minority equity stakes and often co-invests with other venture and corporate funds. Their strategy revolves around identifying and nurturing groundbreaking innovations that improve farming economics and productivity. The average check size varies, but they actively lead rounds, particularly in Series B and beyond. Entrepreneurs are encouraged to approach them with scalable solutions that align with their mission of sustainable and profitable agriculture. The leadership team, including Managing Directors Michael Lee and Shubhang Shankar, brings extensive expertise in venture capital, technical sciences, and agribusiness. Syngenta Group Ventures stands out for its deep industry knowledge and commitment to leveraging technology for a better agricultural future.

Systemiq Capital is a London-based venture capital firm focused on accelerating the transition to a sustainable, net-zero economy by investing in climate tech startups. Launched in 2018 as the investment arm of Systemiq, the firm targets early-stage companies from late seed to Series A/B funding, concentrating on sectors like sustainable food and materials, clean transportation, climate intelligence, and climate restoration. Led by industry leaders like Paul Polman and Jeremy Oppenheim, Systemiq Capital goes beyond traditional venture funding by connecting startups with a global ecosystem of corporate leaders, policymakers, and climate experts. This support helps portfolio companies navigate complex regulatory environments and scale more effectively. Their portfolio includes companies like ZeroAvia, which pioneers hydrogen-powered aviation, and Nature Metrics, which developed the world’s largest environmental DNA database to monitor biodiversity impacts. With the launch of their second fund, Systemiq Capital has secured $70 million of its $200 million target to further back climate innovators. The firm seeks to drive systemic change by supporting startups that can deliver substantial environmental impact while also generating strong financial returns.

T2 Venture Creation (T2VC) is a Silicon Valley seed and early-stage venture capital and advisory firm focused on high-impact innovation in the technology and healthcare sectors. Created in the mid-2000s and headquartered in Portola Valley, California, it was founded as the venture capital affiliate of the Larta Institute, which remained a partner. T2VC's distinctive model invests both money and time in startups spinning out of academia and government, drawing its deal pipeline from the National Institutes of Health, DARPA, the NIST Advanced Technology Program, more than 50 universities, and a network of over 40 innovation clusters across more than 20 countries. Typical deals fell in the $1M to $5M range, usually in rounds with two or three co-investors such as Tamiami Angel Funds, St. Louis Arch Angels and GSR Ventures. Areas of investment spanned biotechnology, water and water purification, nanotechnology, RFID, apps and education. Portfolio companies included GroundMetrics in electromagnetic sensing, Independa in aging-in-place healthcare technology, Liquidity Nanotech in nanotech water filtration and Stonybrook Purification. The firm is led by co-founders Victor W. Hwang, CEO and immediate past President of the Larta Institute, and Greg Horowitt, Managing Director, Executive Director of Global CONNECT and co-author of 'The Rainforest: The Secret to Building the Next Silicon Valley.' Its most active period was the early 2010s; tracked investment activity tapered after 2013 to 2014 as the principals moved into broader innovation-ecosystem roles. T2VC pioneered a hands-on model for commercializing academic and government research.

TA Ventures, founded in 2010 and headquartered in Kyiv, Ukraine, specializes in early-stage investments in tech startups. The firm focuses on sectors such as SaaS, AI, fintech, e-commerce, and digital health. TA Ventures has a significant portfolio of over 120 companies, including notable investments like Wrike, Rentberry, and Jiji. The firm typically invests in pre-seed and seed stages with average ticket sizes ranging from $100,000 to $500,000. They seek out ambitious startups with scalable business models and global potential. TA Ventures has a strong track record of successful exits, with over 42 companies having been acquired or gone public. Key team members include Viktoriya Tigipko, the Founder and Managing Partner, who has a rich background in entrepreneurship and technology, and Oleg Malenkov, a Partner based in Los Angeles who focuses on consumer tech. The team is spread across various locations, including the US, the Netherlands, and Southeast Asia, enabling them to leverage a broad network and diverse market insights. TA Ventures also co-invests with other prominent venture funds and angels, further supporting the growth and scalability of their portfolio companies.

Tabula Rasa Ventures is an investment firm specializing in healthcare and biotechnology, with a strong focus on psychedelic therapeutics. Founded in 2018, the firm seeks to fill critical gaps in the healthcare industry by investing in innovative startups across the biotech, drug development, and digital health sectors. Headquartered in New York, Tabula Rasa Ventures has become a leader in the psychedelic ecosystem, providing early-stage capital, incubation, and acceleration for groundbreaking ventures. The firm's investment strategy revolves around supporting startups from their inception through growth stages. They work hands-on with founders, offering deep expertise in scaling, regulatory affairs, and clinical trials. Tabula Rasa has built a diverse portfolio of companies like ATAI Life Sciences, Wavepaths, and Lykos Therapeutics, all of which are pushing the boundaries of mental health treatment and healthcare infrastructure. Led by Managing Partners Marik Hazan and Maria Velkova, Tabula Rasa Ventures takes a community-driven approach. They emphasize sustainable long-term growth by fostering trust among stakeholders, whether they are investors, patients, or regulators. With investments ranging from $50,000 to $1 million, the firm remains committed to transforming healthcare through cutting-edge solutions that address significant unmet needs in mental health and beyond. Their involvement in conferences such as the World Economic Forum.

Takeda Ventures, Inc. (TVI), founded in 2001, is the corporate venture capital arm of Takeda Pharmaceutical Company Limited. TVI focuses on early-stage, preclinical opportunities that align with Takeda's R&D pillars: Oncology, Rare Genetics & Hematology, Neuroscience, and Gastrointestinal & Inflammation. Their portfolio includes notable companies such as Amwell, Avidity Biosciences, and Xilio Therapeutics. TVI's investment strategy emphasizes high-caliber, therapeutic, platform-based companies worldwide, primarily in North America, Europe, and Japan. The average investment ranges from seed to Series B rounds, with TVI often co-investing alongside major venture firms like OrbiMed and Johnson & Johnson Innovation. TVI's approach includes taking board seats and providing strategic guidance, leveraging Takeda's extensive global resources and expertise to drive value-based outcomes for patients. The team is based in Cambridge, MA, and includes seasoned professionals like Miles Gerson (Head & President) and Jasmina Marjanovic, Ph.D. (Partner). They prioritize a hands-on, collaborative approach, working closely with portfolio companies to foster innovation and therapeutic advancements. TVI actively seeks to build relationships with academic innovators, entrepreneurs, and venture investors to cultivate a robust pipeline of breakthrough therapies. For startups looking to connect, TVI values companies with early commercial traction and those that embody a patient-first approach, reflecting Takeda’s core values.

Takeda Ventures, Inc. (TVI) is the corporate venture capital group of Takeda Pharmaceutical Company Limited, Japan's largest pharmaceutical company, founded in 2001 with the vision of generating disruptive technologies and therapeutic solutions for patients through venture-based investments. Operating under Takeda's Center for External Innovation, the firm specifically backs early-stage, preclinical opportunities and platform-based therapeutic companies around the world whose products complement Takeda's pipeline. Its investments are aligned with Takeda's core R&D pillars: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastrointestinal and Inflammation. As a strategic co-investor, TVI partners with academic innovators, entrepreneurs and venture investors, offering portfolio companies access to the deep therapeutic-area expertise, translational capabilities and resources of a multinational pharmaceutical company. Across its history the firm has made well over a hundred investments, producing 8 IPOs and 15 acquisitions, with notable exits including HOOKIPA Pharma, Avidity Biosciences and BiomX, and recent portfolio additions such as Accipiter Biosciences, Integra Therapeutics and Degron Therapeutics. The group remained highly active through 2024 and 2025, completing fresh oncology and biotech rounds. Takeda Ventures is led by President and CEO Graeme R. Matin and a team of roughly eleven, with primary investment activity across the United States, Western Europe and Canada. A separate sister unit, Takeda Digital Ventures, founded in 2018, focuses on digital health. By pairing capital with Takeda's translational and therapeutic expertise, TVI backs the preclinical and platform companies most relevant to its parent's pipeline.

Tall Grass Ventures (TGV) is an early-stage venture capital firm founded in 2022 and based in Calgary, Canada, investing in the future of agriculture and food. With roots in the Canadian prairies and a global vision, the firm provides funding and hands-on support to transformative entrepreneurs developing innovative agtech and foodtech solutions across livestock production, automation, crop protection and fertility, next-generation ingredients, protein production, risk management, decarbonization and digital transformation. TGV focuses primarily on pre-seed and seed-stage companies, with seed rounds averaging around $2.6M and a Series A around $3.5M, believing agriculture is underserved by innovation investment and that founders need real, tactical support more than just capital; it views the value it adds through its curated ecosystem as being as important as economics, typically participating as a co-investor. The firm closed its oversubscribed inaugural fund at $32 million in July 2024, backed by limited partners including leading grain and livestock producers from Manitoba to British Columbia, livestock feeders, commodity brokers and traders, financial-service firms, private-equity investors and technology founders. Its portfolio of about 11 companies spans the agrifood supply chain, from gene editing and biological solutions to software and hardware for specialty crops, plant-tissue sampling and grain grading, with names including IntelliCulture, GeneNeer and Sensor Globe. TGV is led by managing partners Wilson Acton, a four-time tech startup founder, and Chris Edwards, supported by a team of seven including venture partners across Canada and the United States. The firm pairs deep prairie agriculture roots with tactical founder support.

Tao Capital Partners, based in San Francisco, is a versatile venture capital firm known for its broad investment scope and influential portfolio. Notable investments include high-profile companies like Tesla, Uber, SpaceX, and DeepMind, showcasing their commitment to technology, alternative energy, and transportation. They also have significant stakes in sectors such as healthcare, education, sustainable food, and real estate, with investments in companies like Warby Parker, Harry's, and Zymergen. Tao Capital's investment strategy is flexible, engaging with companies across various stages of their lifecycle. They seek out businesses that have a positive impact and support them actively through their growth. Their geographic focus spans primarily North America, particularly the United States, although they do not restrict themselves geographically. The firm’s approach is hands-on, often taking board seats and leveraging their extensive network to add value beyond just capital. They are known for their active involvement in portfolio companies, ensuring they align with Tao’s values and long-term vision. Their team includes experienced professionals with deep industry knowledge, contributing to their strategic investment decisions. For startups looking to connect, Tao Capital prefers those that can demonstrate early traction and have a clear, positive impact. They value innovative solutions that align with their diverse investment interests, ranging from cutting-edge technology to sustainable food and agriculture​.

Target Global is a Berlin-based venture capital firm, managing over €1 billion in assets. It focuses on backing fast-growing startups in fintech, SaaS, mobility, and digital health across Europe, Israel, and the US. Their portfolio includes major players like Delivery Hero, WeFox, and Rapyd. With a focus on seed to growth-stage companies, Target Global typically invests €10-20 million, actively leading rounds and guiding companies through to international success. The firm’s strategy centers on identifying disruptive digital-enabled businesses, often those in underserved markets or emerging sectors like Industry 4.0 and healthtech. Their geographic focus spans Europe, with particular emphasis on Germany, London, and Tel Aviv, but they also make opportunistic investments in emerging economies like Poland and the Baltics. In terms of recent activity, Target Global raised a new €300 million fund to deepen its exposure in fintech and wellness sectors. The firm typically invests 70% of its capital in Europe, 20% in Israel, and the rest in opportunistic global deals. Entrepreneurs seeking funding are encouraged to highlight scalable, tech-driven solutions, as Target looks for businesses that can drive industry-wide change. Led by general partners Yaron Valler and Alex Frolov, the firm combines deep market knowledge with a proactive, hands-on approach, making it a key player in Europe’s venture capital scene.

Tarnagulla Ventures is a life-science-focused venture capital firm founded in 2015 and headquartered in Melbourne, Australia, providing seed and venture capital to promising companies in the healthcare and life-science space. Although Melbourne-based, the firm is global in scope with a particular focus on bringing promising medical technologies to the Australian and US markets, and it backs companies primarily at the seed and Series A stages, willing to lead rounds. Its expertise spans small-molecule, protein and cell-based therapeutics, and it positions itself as a strategic partner that contributes intellectual as well as financial capital. The firm is named after Tarnagulla, an old Australian gold-mining town with family ties to its founders, where the 26.6kg 'Poseidon' gold nugget was found in 1906. Tarnagulla is managed by William and Natalie McNamee: Natalie has been a director since 2015 and leads investment diligence across most portfolio companies, while William, a director since 2016, co-founded and led the development of three life-science companies, Holman Pharmaceuticals, Dalmoral Pharmaceuticals and LimRad. Across roughly eight portfolio companies the firm has notched two NASDAQ IPOs: LB Pharmaceuticals, developer of LB-102 for schizophrenia, listed in September 2025 at a roughly $302M market cap, and Jupiter Neurosciences, whose resveratrol-platform JOTROL targets CNS diseases, exited via IPO in December 2024 at a roughly $132M market cap and whose $2M seed round Tarnagulla led. Other holdings include Azora Therapeutics in autoimmune and inflammatory small molecules and Prevatex in maternal-microbiome probiotics. The firm reported no new investments in 2025.

Tau Ventures, founded in 2019 and based in Palo Alto, California, is a venture capital firm that focuses on early-stage investments in AI-driven technologies. Their investment portfolio spans sectors such as digital health, enterprise software, and automation, including robotics and drones. They typically write initial checks between $500,000 and $1 million, providing seed funding to startups with significant growth potential. The firm was co-founded by Amit Garg and Sanjay Rao, both experienced in venture capital and technology. Amit Garg, with a background from Google and Norwest Venture Partners, focuses primarily on digital health investments. Sanjay Rao, previously with McKinsey and Microsoft, concentrates on enterprise and automation sectors. The team also includes associates like Sharon Huang and Insoo Chang, who bring diverse expertise from biotechnology to strategic investments. Tau Ventures is recognized for its active engagement with portfolio companies, providing strategic guidance and leveraging their extensive network to help startups succeed. Some notable investments include Alaffia Health, a healthcare technology firm, and Tonic, which creates synthetic data for testing and development. With around $85 million in assets under management, Tau Ventures is committed to fostering innovation in AI and supporting startups that aim to make a significant impact in their respective fields​.

Teamworthy Ventures is a venture capital firm that invests in early to growth-stage companies, focusing on building long-term relationships with talented entrepreneurial teams. Their portfolio includes leading software and software-enabled services companies such as Toast, SeatGeek, Weave, Carta, Capsule, CampusLogic, G2, Ibotta, OpenGov, Foursquare, Vestwell, Affinity, and Slice. The firm's mission is to partner with outstanding entrepreneurial teams to build companies of purpose, integrity, and enduring value. They emphasize values such as teamwork, service, integrity, creativity, enthusiasm, initiative, craftsmanship, learning, prudence, fortitude, humility, and thrift. Teamworthy strives to be a worthy partner by providing not just capital but also strategic support and mentorship to help entrepreneurs achieve their full potential. Their investment team includes experienced professionals like Senior Associate Kyle Limpic, Associate Emma Barrett, and Associate Josiah Meadows, who bring diverse backgrounds and expertise to the firm. Teamworthy Ventures operates out of Greenwich, Connecticut, and Nashville, Tennessee, providing a robust support network for their portfolio companies.

Tech Coast Angels (TCA) is one of the largest and most active angel investor networks in the U.S., particularly focused on Southern California. Since its founding in 1997, TCA has funded over 540 companies, providing more than $300 million in early-stage capital. Its portfolio includes notable successes such as Apeel (now a unicorn) and Procore. TCA’s investments span a variety of industries, including healthcare, high-tech, and consumer products. TCA primarily invests in seed and early Series A rounds, often in California-based startups but also extending its reach across the U.S. and occasionally internationally. The group is known for not only providing capital but also hands-on mentorship and operational support. With around 400 members across several regional networks, TCA brings deep expertise and valuable connections to the table. Recently, TCA has increased its focus on syndicating deals with other angel groups and VCs, helping startups secure additional capital. Entrepreneurs looking to partner with TCA should demonstrate strong market potential and scalability, while leveraging the network’s robust mentorship and support system to build a sustainable business​.

Tech Council Ventures is an early-stage venture capital firm based in Summit, New Jersey that invests Seed and Series A financing into the Mid-Atlantic region's most promising growth technology companies. Originally founded in 2001 as the NJTC Venture Fund, it rebranded to Tech Council Ventures in 2016 and operates as the venture arm of TechUnited:NJ, formerly the NJ Technology Council, one of the largest and most active technology councils in the United States with more than 500,000 innovator members. That affiliation is the firm's core differentiator: portfolio companies gain access to an unmatched network of customers, key team recruits, business partners and service providers. With roughly $175M in assets under management across eight funds and five decades of collective team experience, the firm writes checks of $500K to $3M into startups spanning technology, enterprise software, biotech, life sciences, healthcare, media, telecom, cleantech and edtech, and it is willing to lead rounds. Its investment team is led by Managing Partner and Founder Jim Gunton, a 20-plus-year investor formerly with Edison Venture Fund and Oracle, alongside Managing Partner Steve Socolof and Partner Mark Kolb, a healthcare entrepreneur and former CEO of Bergen Medical Products. Tech Council Ventures has made roughly 59 investments with four exits, including notable holdings such as Achieve3000, Amber Road, CytoSorbents, InstaMed and IntegriChain. The firm is currently deploying its third fund; its most recent investment was participation in PolyGone Systems' $4M Seed round in February 2026. By tying its capital to one of the country's largest technology-council networks, the firm backs Mid-Atlantic founders.

TechAccel (Technology Acceleration Partners) is a Kansas City-area technology and venture development organization founded in 2014 by Michael Helmstetter together with Kansas State University and the Bicknell Family Holding Company. It describes itself as a first-of-its-kind hybrid that pairs equity capital with R&D: its 'Equity+ Science Advancement' model invests in startups and simultaneously funds research at universities and partners to bridge the gap between scientific discovery and commercialization. The firm focuses on agriculture (agtech), animal health and nutrition, and food technology, sectors its leadership argues are under-appreciated by mainstream venture capital that concentrates on human health. Rather than operating as a conventional pooled fund, TechAccel is an operating company backed by Kansas City-based high-net-worth individuals and family offices, calling capital as needed to fund specific projects; individual investments typically range from about $500,000 to $1 million, and it generally invests as a co-investor. It is led by Co-Founder, President and CEO Dr. Michael Helmstetter, who brings more than 30 years of startup, spin-off and technology-advancement experience across agriculture, defense and biotechnology. TechAccel's portfolio of roughly a dozen disclosed companies has produced one IPO, GreenLight Biosciences, and one acquisition, Agrivida, and includes investments such as Benson Hill Biosystems, where it joined a $25M Series B in crop science, and Epicrop Technologies, a crop-epigenetics company. It also co-formed Covenant Animal Health Partners, later sold to NovaQuest Capital Management in 2021. By coupling equity investment with funded science advancement, TechAccel backs agriculture, animal-health and food-technology innovation from discovery through commercialization.

Techstars is a global platform for investment and innovation that has supported over 4,000 startups since its inception in 2006. Based in Boulder, Colorado, Techstars operates accelerator programs worldwide, providing early-stage startups with access to capital, mentorship, and a vast network of investors and partners. Their portfolio spans a diverse range of industries, including HealthTech, FinTech, Web3, CleanTech, and more. Notable companies in their portfolio include Chainalysis, DataRobot, and Remitly. Techstars has facilitated over $27.3 billion in total funding for its startups, with a cumulative market cap of $113.6 billion​. Techstars' investment strategy involves pre-seed and early-stage investments through their accelerator programs. They invest up to $120,000 in each startup during the accelerator program, and follow-on investments through their Venture Fund. This strategy allows them to support companies from their initial stages through to growth​.

Techstart Ventures is a seed-stage venture capital firm founded in 2014 and based in Belfast, Northern Ireland, that backs the most ambitious entrepreneurial founding teams across Northern Ireland and Scotland. It invests from inception to pre-seed stage, writing first cheques of up to £750k with capacity for follow-on, and looks for exceptional founders pursuing uncapped global opportunities from a base in either region, willing to lead rounds. The firm manages around £50m of equity funds alongside a £4.5m proof-of-concept grant fund; in Scotland it runs the Scottish Growth Scheme Techstart Ventures Equity Finance LP, financed with support from the Scottish Government and the European Regional Development Fund, building on its earlier track record of backing 44 seed-stage technology companies in Northern Ireland. Techstart is unusually open to cold inbound and places heavy weight on founder references from companies it has already backed. Its team of roughly ten includes partners Mark Hogarth, Hal Wilson and Jamie Andrews, spanning venture investing, biotech and technology commercialization, and investment strategy. Across its funds it has backed roughly 118 companies over more than a decade, averaging seven to eight new investments a year across software, SaaS, enterprise software, fintech and biotech. Notable portfolio companies include Cloudsmith, a Belfast-founded cloud-native software supply chain security and package management platform; Raylo, a gadget lease-and-reuse fintech; and Neurovalens. A recent portfolio exit was Loveelectric, acquired by Perkbox in December 2025. By anchoring itself in Northern Ireland and Scotland and backing founders from inception, Techstart fuels two underserved regional ecosystems.

TEN13 is an innovative venture capital firm based in Fortitude Valley, Australia, co-founded by Stew Glynn and Steve Baxter in 2019. TEN13 operates on a deal-by-deal investment model, allowing its network of over 500 investors to choose specific deals they want to back. This model offers flexibility and targeted investment opportunities, enabling investors to allocate capital more precisely. TEN13 focuses on early-stage investments in diverse sectors, including fintech, health and wellbeing, education, and AI. Notable portfolio companies include Clipchamp, an online video editing platform acquired by Microsoft, Go1, an online learning platform that recently raised $200 million from Softbank, and Chipper Cash, a leading African fintech app. The firm has seen significant growth, deploying over $70 million across 32 startups since its inception. TEN13 is known for its supportive approach, providing more than just capital. They offer strategic guidance, network connections, and operational support to help startups scale effectively. This hands-on approach has been a key factor in their success, with several of their portfolio companies achieving substantial growth and recognition. TEN13’s team includes experienced professionals like Sophie Robertson, who was recently promoted to Partner, and Joel Pobar, who joined as a Venture Partner to strengthen their AI investments. The firm continues to expand its presence, recently building connections in Southeast Asia and North America to support and discover new opportunities.

Tensor Ventures is a Prague-based, Luxembourg-domiciled deep-tech venture capital firm founded in 2018 that invests in frontier technologies and sustainable innovation across Central and Eastern Europe and beyond. The firm focuses on sectors it describes itself as fluent in: artificial intelligence, quantum technologies, computational biotech (techbio), semiconductors and sustainable and space technology. It participates in Seed and Series A rounds, sometimes leading and sometimes co-investing with trusted partners, and sources deals through proprietary methods including university referrals and partnerships with corporates such as Intel and NVIDIA. Tensor's first fund deployed roughly EUR 18.5M to EUR 20M into about 20 startups over four years and ranked in the top 20% of VC funds; in October 2024 it announced a second EUR 50M deep-tech fund, with the European Investment Fund committing EUR 20M, allocating roughly half its capital to Czech startups and half globally. Seed investments have averaged about $1.66M round size and its three Series A rounds around $16.5M. Across a portfolio of about 27 companies, notable holdings include Heartbeat.bio, Stacktape, Quantagonia, Antiverse, Anari.ai, Beit, QC82, DYNANIC and exits Neuronix and ultimate.suit. The firm is led by founders and general partners Martin Drdul and Roman Smola, with Petr Ulvr leading business development. Its most recent disclosed deal was leading a roughly $4M seed round in London-based enterprise-app modernization startup AppFactor, announced in January 2026. Tensor Ventures pairs deep-tech specialization with strong university and corporate sourcing across the CEE region.

Tet Ventures is an early-stage venture capital firm focused on rebuilding the global food system through bold innovation and sustainable solutions. Founded in 2020 by Neeraj Berry, Tet invests between $50K and $250K in foodtech startups worldwide, particularly across the U.S. and Europe. With a mission to solve some of the most pressing issues facing food production and sustainability, their portfolio includes pioneering companies like Arkeon, which uses CO2 to create food ingredients, and Impetus Ag, which develops novel agricultural technologies. Although primarily focused on foodtech, Tet occasionally backs startups in other sectors if they align with their vision of generational entrepreneurship. The firm actively seeks out businesses that are not just high-growth but built to last, supporting founders with capital, strategic mentorship, and access to an extensive network of experts. Tet Ventures operates from Berlin and frequently collaborates with other investors to accelerate the growth of early-stage companies. In addition to their investments, Tet fosters a community-centered approach, encouraging meaningful dialogue around sustainability and food system innovation. Startups are encouraged to approach Tet Ventures with a clear, impactful vision, as the firm emphasizes long-term potential over quick returns. With a strong belief in generational change, Tet Ventures aims to be a key player in driving forward a more sustainable, equitable future in global food systems, all while maintaining the flexibility to support projects with transformative potential outside the food sector.

The Ambition Fund, founded by Tanya Sam, is a venture capital firm dedicated to funding women and underrepresented minority entrepreneurs. Based in Atlanta, Georgia, the fund focuses on early-stage and seed-stage investments across diverse sectors, including consumer products, media, and technology. Its mission is to provide opportunities for founders who traditionally face barriers in accessing venture capital, promoting diversity and inclusion within the startup ecosystem​. Tanya Sam, a tech entrepreneur and television personality known for her role on The Real Housewives of Atlanta, leads the fund with a deep commitment to fostering innovation and economic empowerment. In addition to her work with The Ambition Fund, she is the Director of Partnerships at TechSquare Labs and co-leads the Ascend Atlanta program, which has helped over 60 companies, collectively generating over $100 million in revenue. Her strong background in tech and business development has positioned her as a key advocate for underrepresented founders. The Ambition Fund actively seeks out innovative startups with high growth potential and social impact. The fund typically makes investments ranging from $100,000 to $500,000. It has also launched initiatives such as the Business Battle Pitch Competition, which provides an interactive platform for minority entrepreneurs to pitch their ideas and secure fundin. By providing capital, mentorship, and strategic support, The Ambition Fund aims to elevate a new generation of diverse founders and drive meaningful change in the venture capital landscape.

TCG, formerly known as The Chernin Group, is a venture capital firm specializing in consumer businesses across various industries, from media to health and wellness, gaming, and consumer finance. Notable investments include Headspace, Barstool Sports, Crunchyroll, and Food52. TCG's strategy revolves around identifying strong consumer brands with passionate fan bases and solid business models, often in direct-to-consumer and subscription-based businesses. They aim to partner with management teams that have already established great brands but need assistance in scaling further​. Geographically, TCG focuses on investments in North America, with offices in Los Angeles, San Francisco, and New York. The firm typically leads rounds, leveraging its extensive network and expertise to provide significant operational support and access to capital. They recently closed a new fund with over $700 million in commitments, showcasing their robust financial backing and commitment to future investments. The team comprises seasoned professionals like Peter Chernin, Jesse Jacobs, and Mike Kerns, who bring a wealth of experience from their previous roles in major companies like News Corp and Yahoo!. This diverse team shares a common drive and curiosity, crucial for identifying and nurturing the next big consumer trends​. For startups looking to approach TCG, it's best to highlight how your company aligns with evolving consumer behaviors and demonstrates potential for strong brand identity and a loyal customer base. They value founders who have done the hard work in building their brands and are ready to scale with the right strategic support.

The Community Fund is a $5 million early-stage venture capital fund launched in 2020, focused on investing in community-driven companies. Co-founded by Lolita Taub, the fund believes that building strong, vibrant communities can create a competitive advantage for startups. The fund typically invests at the pre-seed and seed stages, aiming to support founders who are leveraging community as a core element of their business models. The Community Fund has backed over 40 companies across various sectors, including health, wellness, and tech. Some of its notable investments include Elektra Health and Kindra, both of which focus on empowering communities through innovative health solutions. The fund operates with a diverse team of investment partners, ensuring broad expertise and support for the startups they work with. With a strong mission to drive inclusive innovation, The Community Fund prioritizes working with underrepresented founders, ensuring that community-building is not only a business strategy but also a tool for social impact. Their investment approach goes beyond financial backing, offering mentorship, strategic guidance, and access to a vast network of industry experts to help startups succeed.

E14 Fund is an MIT-affiliated venture capital firm focused on supporting deep-tech startups emerging from the MIT community. Established in 2013 and rooted in the MIT Media Lab, the fund specializes in companies that are addressing critical global challenges through breakthrough science and engineering. E14 Fund invests in early-stage startups, typically from pre-seed to Series A, with a focus on industries such as robotics, artificial intelligence, quantum computing, and synthetic biology. Some notable investments include Formlabs, a leader in 3D printing technology, and Overjet, a pioneer in AI-powered dental care solutions. The fund is more than just a capital provider; it acts as a strategic partner, helping founders transition from academic research to building scalable businesses. E14 leverages the vast MIT network to connect entrepreneurs with industry leaders, mentors, and technical resources that can help accelerate their growth. A significant portion of the firm’s profits is reinvested into MIT, highlighting its commitment to fostering long-term innovation within the university ecosystem. Led by managing partners Calvin Chin and Habib Haddad, E14 Fund works closely with founders to address both scientific and business challenges, providing hands-on support throughout their journey. The fund’s portfolio companies typically possess unique intellectual property and a clear path to market dominance, reflecting E14’s focus on ventures with transformative potential. By supporting startups from their earliest stages, E14 Fund plays a crucial role in translating groundbreaking MIT research into impactful, market-ready technologies.